Datamonitor Healthcare

Immuno-Oncology Overview

By Colin White, Robert Jeng & Jolene Lau 28 Jul 2022

This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well

Datamonitor Healthcare, Biomedtracker

2019 Q3 Outlook Webinar

By Hardik Patel 15 Jul 2019

Pharma Intelligence presents an essential, free session during which industry analysts present their data-driven views about what to expect during the third quarter of 2019. 

Scrip

BMS' Opdivo Approval In CRC Overshadowed By Keytruda Dominance

02 Aug 2017

The US FDA has approved BMS' Opdivo for previously treated patients with some forms of colorectal cancer, however direct competition from Merck's Keytruda may limit its success.

Scrip

PD-1 Data Emerges In Cervical Cancer

By Lucie Ellis 26 Jul 2017

Leading immunotherapy agents are beginning to report early-stage data from monotherapy and combination trials in advanced cervical cancer – a treatment area with very few approved options.

Scrip

NSCLC Momentum Goes To Merck And Roche, Bodes Well For Combinations

By Joseph Haas 13 Feb 2017

New cancer immunotherapies are doing well in lung cancer, with Merck's Keytruda picking up share in the first-line setting and Roche's Tecentriq in second-line. Bristol-Myers Squibb is banking on combo therapy to restore its momentum.

Scrip

Therapeutic Progress Amid Political Turbulence: Could 2017 Be Pharma's Year?

12 Dec 2016

Delivering clinical advances in areas including immuno-oncology and Alzheimer's disease data while navigating the stormy seas of global politics could represent an opportunity for pharma to influence change. An uptick in sector M&A could also ensue if Trump offers US corporations a tax holiday.

Scrip

Merck's Keytruda Chemo-Combo Data Has Big Implications For Future Of Immuno-Oncology

By Jessica Merril 10 Oct 2016

Merck’s strong Phase II data testing Keytruda with chemotherapy

Biomedtracker

​Analyzing ASCO 2016

13 Jun 2016

Datamonitor Healthcare

Need help entering the Ulcerative Colitis market?

13 Sep 2015

Entering an established market as a new player can be daunting. Often it's difficult to know exactly where you should be targeting your trial, and also what patient group you should be targeting your treatment at.